Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update

Jacek Gronwald, Nadine Tung, William D. Foulkes, Kenneth Offit, Ruth Gershoni, Mary Daly, Charmaine Kim-Sing, Hakan Olsson, Peter Ainsworth, Andrea Eisen, Howard Saal, Eitan Friedman, Olufunmilayo Olopade, Michael Osborne, Jeffrey Weitzel, Henry T. Lynch, Parviz Ghadirian, Jan Lubinski, Ping Sun, Steven A. NarodD. Gilchrist, B. Weber, T. Rebbeck, C. Isaacs, S. Neuhausen, J. Garber, B. Karlan, D. Fishman, S. Merajver, W. McKinnon, M. Wood, G. Evans, P. Moller, B. Pasini, K. Sweet, C. Eng, G. Rennert, F. Couch, J. McLennan, D. Provencher

Research output: Contribution to journalReview article

210 Citations (Scopus)

Abstract

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of ∼80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is ∼30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of breast cancer and had been followed for as long as the case for a second primary breast cancer. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.30-0.85) and was 0.42 for carriers of BRCA2 mutations (95% CI, 0.17-1.02). The protective effect of tamoxifen was not seen among women who had undergone an oophorectomy (OR = 0.83; 95% CI, 0.24-2.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27-0.65).

Original languageEnglish
Pages (from-to)2281-2284
Number of pages4
JournalInternational Journal of Cancer
Volume118
Issue number9
DOIs
StatePublished - May 1 2006

Fingerprint

Tamoxifen
Breast Neoplasms
Ovariectomy
Mutation
Second Primary Neoplasms
Menopause
Case-Control Studies
History
Odds Ratio

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M., ... Provencher, D. (2006). Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. International Journal of Cancer, 118(9), 2281-2284. https://doi.org/10.1002/ijc.21536

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers : An update. / Gronwald, Jacek; Tung, Nadine; Foulkes, William D.; Offit, Kenneth; Gershoni, Ruth; Daly, Mary; Kim-Sing, Charmaine; Olsson, Hakan; Ainsworth, Peter; Eisen, Andrea; Saal, Howard; Friedman, Eitan; Olopade, Olufunmilayo; Osborne, Michael; Weitzel, Jeffrey; Lynch, Henry T.; Ghadirian, Parviz; Lubinski, Jan; Sun, Ping; Narod, Steven A.; Gilchrist, D.; Weber, B.; Rebbeck, T.; Isaacs, C.; Neuhausen, S.; Garber, J.; Karlan, B.; Fishman, D.; Merajver, S.; McKinnon, W.; Wood, M.; Evans, G.; Moller, P.; Pasini, B.; Sweet, K.; Eng, C.; Rennert, G.; Couch, F.; McLennan, J.; Provencher, D.

In: International Journal of Cancer, Vol. 118, No. 9, 01.05.2006, p. 2281-2284.

Research output: Contribution to journalReview article

Gronwald, J, Tung, N, Foulkes, WD, Offit, K, Gershoni, R, Daly, M, Kim-Sing, C, Olsson, H, Ainsworth, P, Eisen, A, Saal, H, Friedman, E, Olopade, O, Osborne, M, Weitzel, J, Lynch, HT, Ghadirian, P, Lubinski, J, Sun, P, Narod, SA, Gilchrist, D, Weber, B, Rebbeck, T, Isaacs, C, Neuhausen, S, Garber, J, Karlan, B, Fishman, D, Merajver, S, McKinnon, W, Wood, M, Evans, G, Moller, P, Pasini, B, Sweet, K, Eng, C, Rennert, G, Couch, F, McLennan, J & Provencher, D 2006, 'Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update', International Journal of Cancer, vol. 118, no. 9, pp. 2281-2284. https://doi.org/10.1002/ijc.21536
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. International Journal of Cancer. 2006 May 1;118(9):2281-2284. https://doi.org/10.1002/ijc.21536
Gronwald, Jacek ; Tung, Nadine ; Foulkes, William D. ; Offit, Kenneth ; Gershoni, Ruth ; Daly, Mary ; Kim-Sing, Charmaine ; Olsson, Hakan ; Ainsworth, Peter ; Eisen, Andrea ; Saal, Howard ; Friedman, Eitan ; Olopade, Olufunmilayo ; Osborne, Michael ; Weitzel, Jeffrey ; Lynch, Henry T. ; Ghadirian, Parviz ; Lubinski, Jan ; Sun, Ping ; Narod, Steven A. ; Gilchrist, D. ; Weber, B. ; Rebbeck, T. ; Isaacs, C. ; Neuhausen, S. ; Garber, J. ; Karlan, B. ; Fishman, D. ; Merajver, S. ; McKinnon, W. ; Wood, M. ; Evans, G. ; Moller, P. ; Pasini, B. ; Sweet, K. ; Eng, C. ; Rennert, G. ; Couch, F. ; McLennan, J. ; Provencher, D. / Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers : An update. In: International Journal of Cancer. 2006 ; Vol. 118, No. 9. pp. 2281-2284.
@article{5a3932ebe2bc48a38259e6f1d3febf9b,
title = "Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update",
abstract = "Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of ∼80{\%}, and following the first diagnosis the 10-year risk of contralateral breast cancer is ∼30{\%}. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of breast cancer and had been followed for as long as the case for a second primary breast cancer. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95{\%} CI, 0.30-0.85) and was 0.42 for carriers of BRCA2 mutations (95{\%} CI, 0.17-1.02). The protective effect of tamoxifen was not seen among women who had undergone an oophorectomy (OR = 0.83; 95{\%} CI, 0.24-2.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95{\%} CI, 0.27-0.65).",
author = "Jacek Gronwald and Nadine Tung and Foulkes, {William D.} and Kenneth Offit and Ruth Gershoni and Mary Daly and Charmaine Kim-Sing and Hakan Olsson and Peter Ainsworth and Andrea Eisen and Howard Saal and Eitan Friedman and Olufunmilayo Olopade and Michael Osborne and Jeffrey Weitzel and Lynch, {Henry T.} and Parviz Ghadirian and Jan Lubinski and Ping Sun and Narod, {Steven A.} and D. Gilchrist and B. Weber and T. Rebbeck and C. Isaacs and S. Neuhausen and J. Garber and B. Karlan and D. Fishman and S. Merajver and W. McKinnon and M. Wood and G. Evans and P. Moller and B. Pasini and K. Sweet and C. Eng and G. Rennert and F. Couch and J. McLennan and D. Provencher",
year = "2006",
month = "5",
day = "1",
doi = "10.1002/ijc.21536",
language = "English",
volume = "118",
pages = "2281--2284",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers

T2 - An update

AU - Gronwald, Jacek

AU - Tung, Nadine

AU - Foulkes, William D.

AU - Offit, Kenneth

AU - Gershoni, Ruth

AU - Daly, Mary

AU - Kim-Sing, Charmaine

AU - Olsson, Hakan

AU - Ainsworth, Peter

AU - Eisen, Andrea

AU - Saal, Howard

AU - Friedman, Eitan

AU - Olopade, Olufunmilayo

AU - Osborne, Michael

AU - Weitzel, Jeffrey

AU - Lynch, Henry T.

AU - Ghadirian, Parviz

AU - Lubinski, Jan

AU - Sun, Ping

AU - Narod, Steven A.

AU - Gilchrist, D.

AU - Weber, B.

AU - Rebbeck, T.

AU - Isaacs, C.

AU - Neuhausen, S.

AU - Garber, J.

AU - Karlan, B.

AU - Fishman, D.

AU - Merajver, S.

AU - McKinnon, W.

AU - Wood, M.

AU - Evans, G.

AU - Moller, P.

AU - Pasini, B.

AU - Sweet, K.

AU - Eng, C.

AU - Rennert, G.

AU - Couch, F.

AU - McLennan, J.

AU - Provencher, D.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of ∼80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is ∼30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of breast cancer and had been followed for as long as the case for a second primary breast cancer. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.30-0.85) and was 0.42 for carriers of BRCA2 mutations (95% CI, 0.17-1.02). The protective effect of tamoxifen was not seen among women who had undergone an oophorectomy (OR = 0.83; 95% CI, 0.24-2.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27-0.65).

AB - Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of ∼80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is ∼30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of breast cancer and had been followed for as long as the case for a second primary breast cancer. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.30-0.85) and was 0.42 for carriers of BRCA2 mutations (95% CI, 0.17-1.02). The protective effect of tamoxifen was not seen among women who had undergone an oophorectomy (OR = 0.83; 95% CI, 0.24-2.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27-0.65).

UR - http://www.scopus.com/inward/record.url?scp=33645675556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645675556&partnerID=8YFLogxK

U2 - 10.1002/ijc.21536

DO - 10.1002/ijc.21536

M3 - Review article

C2 - 16331614

AN - SCOPUS:33645675556

VL - 118

SP - 2281

EP - 2284

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -